Hopp til innhold

Project

Safety, clinical effectiveness, diagnostic accuracy and cost effectiveness of blood-based tests for women with suspected pre-eclampsia - project description

Published Updated

This Health Technology Assessment will evaluate safety, effectiveness, diagnostic accuracy and cost-effectiveness of blood-based tests for women with suspected pre-eclampsia after 20 weeks' gestation.


Summary

The aim of this Health Technology Assessment (HTA) is to evaluate safety, effectiveness, diagnostic accuracy and cost-effectiveness of blood-based tests for pre-eclampsia. The blood-based tests for pre-eclampsia include Elecsys sFlt-1 & PIGF (Preeclampsia), Triage PIGF-test, DELFIA Xpress PIGF 1-2-3 test, BRAHMS sFlt-1 Kryptor/BRAHMS PIGF-pluss Kryptor PE ratio or other relevant blood-based tests for predicting pre-eclampsia after 20 weeks’ gestation. The mandate does not include evaluation of these tests for screening or for routinely testing of high risk groups in early pregnancy. The commissionaire of this HTA is the Commissioning Forum.

See the full project description at Cristin for more information about results, researchers, contact information etc.

Project participants

Project leader

Hilde Tinderholt Myrhaug, Norwegian Institute of Public Health

Project participants

Kjetil Gundro Brurberg, Norwegian Institute of Public Health
Gyri Synnøve Hval Straumann, Norwegian Institute of Public Health
Signe Agnes Flottorp, Norwegian Institute of Public Health
Espen Movik, Norwegian Institute of Public Health
Liv Merete Brynildsen Reinar, Norwegian Institute of Public Health
Anna Stoinska-Schneider, Norwegian Institute of Public Health

About this prosjektet